Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: FROVA

« Back to Dashboard
Frova is a drug marketed by Endo Pharms and Mylan Pharms Inc and is included in two NDAs. It is available from four suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-four patent family members in thirty-three countries.

The generic ingredient in FROVA is frovatriptan succinate. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the frovatriptan succinate profile page.

Summary for Tradename: FROVA

Patents:2
Applicants:2
NDAs:2
Suppliers / Packagers: see list5

Clinical Trials for: FROVA

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 2001RXYes5,464,864<disabled><disabled>
Endo Pharms
FROVA
frovatriptan succinate
TABLET;ORAL021006-001Nov 8, 2001RXYes5,827,871<disabled><disabled>
Mylan Pharms Inc
FROVATRIPTAN SUCCINATE
frovatriptan succinate
TABLET;ORAL202931-001Aug 28, 2014RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FROVA

Drugname Dosage Strength RLD Submissiondate
frovatriptan succinateTablets2.5 mgFrova3/9/2011

Non-Orange Book Patents for Tradename: FROVA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,637,611 Medicaments<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FROVA

Country Document Number Publication Date
Denmark0591280Feb 15, 1999
Netherlands300103Dec 02, 2002
Czech Republic9601506Jun 11, 1997
Poland169410Jul 31, 1996
Slovenia9200125Dec 31, 1992
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc